Jump to content
  • We are now offering Remote Courses

    Equal benefits to our residential courses, without the travel.

    View Courses
  • eLearning Passport

    All our courses. 12 months access. One flat fee.

    More Information
  • Newsletter

    Non-members can signup to keep up to date with RQA news and events.

    Add your details now

EMA - key recommendations in 2021 on the authorisation and safety monitoring of medicines for human use.

16th February 2022

EMA has published an overview of its key recommendations in 2021 on the authorisation and safety monitoring of medicines for human use.

Innovative medicines are essential to advancing public health as they bring new opportunities to treat certain diseases. In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new active substance which had never been authorised in the EU before. The infographic includes a selection of medicines that represent significant progress in their therapeutic areas.

Once a medicine is authorised by the European Commission and prescribed to patients, EMA and the EU Member States continuously monitor its quality and benefit-risk balance and take regulatory action when needed. Measures can include a change to the product information, the suspension or withdrawal of a medicine, or a recall of a limited number of batches. An overview of some of the most notable recommendations is also included in the document.

For more information on the evaluation and authorisation of medicines, please click here.

Back to Recent News

Share

Virtual Event Platform